Goal:
Provide state of the art care for stem cell transplant patients in the outpatient setting

Background:
VICC selected as one of the few authorized treatment centers in the United States approved to administer the first FDA-approved chimeric antigen receptor T cell (CAR T) therapy for treatment of adult patients with a specific type of lymphoma.

VICC is the only cancer center in a seven-state region of the Southeast authorized to deliver the new immunotherapy.

Commercial Car-t patients admitted to the inpatient setting

Innovation:
Telehealth allows APPs to assess, in real time, for CRS and neurotoxicity allowing patients the newest cancer treatment while having increased quality of life outside the hospital.

Expanding the usage and understanding of telemedicine technology among patients

Use of 24/7 specialized APP &MD team allows for continuity of care with patient safety at utmost priority.

Multidisciplinary team approach to outpatient CAR-T has allowed for positive patient experience. Team included MD, APP, PharmD, RN, SW, as well as spanned inpatient providers and nurses, outpatient clinic, and ED specialty training.